Vistagen Therapeutics’ (VTGN) “Neutral” Rating Reiterated at Chardan Capital

Chardan Capital reiterated their neutral rating on shares of Vistagen Therapeutics (NASDAQ:VTGN) in a research report released on Monday morning, Zacks.com reports.

VTGN has been the subject of a number of other research reports. Maxim Group set a $6.00 price target on Vistagen Therapeutics and gave the stock a buy rating in a research report on Thursday, May 2nd. Zacks Investment Research cut Vistagen Therapeutics from a buy rating to a hold rating in a research report on Saturday, May 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $3.55.

VTGN opened at $0.51 on Monday. Vistagen Therapeutics has a 1 year low of $0.38 and a 1 year high of $2.44. The company’s fifty day moving average price is $0.67.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Sphera Funds Management LTD. lifted its position in shares of Vistagen Therapeutics by 37.2% during the 1st quarter. Sphera Funds Management LTD. now owns 2,022,066 shares of the company’s stock worth $2,588,000 after purchasing an additional 548,148 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Vistagen Therapeutics during the 4th quarter worth about $28,000. Geode Capital Management LLC lifted its position in shares of Vistagen Therapeutics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock worth $231,000 after purchasing an additional 17,721 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Vistagen Therapeutics by 168.6% during the 4th quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock worth $104,000 after purchasing an additional 43,714 shares during the last quarter. 14.56% of the stock is owned by institutional investors and hedge funds.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Featured Story: Strangles

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.